Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Sexual dysfunction ın multiple sclerosis: Gender differences.
[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].
MS related employment and disease modifying treatment in the German working population: 1994-2009.
A controlled trial of natalizumab for relapsing multiple sclerosis.
The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
Mesenchymal stem cells as treatment for MS - progress to date.
Vitamin D: a natural inhibitor of multiple sclerosis.
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination.
Fatigue in multiple sclerosis - A brief review.
Nav1.5 sodium channels in macrophages in multiple sclerosis lesions.
Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Submembranous cytoskeletons stabilize nodes of Ranvier.
Substance Name: Naltrexone
Age-dependent effects on the treatment response of natalizumab in MS patients.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis.
Sublime Microglia: Expanding Roles for the Guardians of the CNS.
Rush University Medical Center Sells AMPYRA® Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
Long-Term Results Underscore Value of Early MS Treatment
Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset.
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
Myelin Basic Protein-Specific TCR/HLA-DRB5*01:01 Transgenic Mice Support the Etiologic Role of DRB5*01:01 in Multiple Sclerosis.
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
Progressive multiple sclerosis: The treatment gap.

Pages